“Another kick in the teeth.” Troy Gayeski of SkyBridge Capital, commenting on the 30 percent drop in the price of Irish pharmaceutical maker Shire after U.S. drug company AbbVie confirmed it was cancelling a plan to acquire Shire for $54 billion. Hedge funds including Paulson & Co.
